Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia  by Nguyen, Louis L. et al.
From the Western Vascular Society
Prospective multicenter study of quality of life
before and after lower extremity vein bypass in
1404 patients with critical limb ischemia
Louis L. Nguyen, MD, MBA, MPH,a Gregory L. Moneta, MD,b Michael S. Conte, MD,a Dennis F.
Bandyk, MD,c Alexander W. Clowes, MD,d and B. Lynn Seely, MD,e for the PREVENT III
Investigators Boston, Mass; Portland, Ore; Tampa, Fla; Seattle, Wash; and South San Francisco, Calif
Background: Patients with critical limb ischemia (CLI) have multiple comorbidities and limited life spans. The ability of
infrainguinal vein bypass to improve quality of life (QoL) in patients with CLI has therefore been questioned. Prospective
preoperative and postoperative QoL data for patients undergoing lower extremity vein bypass for CLI are presented.
Methods: A validated, disease-specific QoL questionnaire (VascuQoL) with activity, symptom, pain, emotional, and social
domains and responses scored 1 (lowest QoL) to 7 (best QoL) was administered before surgery and at 3 and 12 months
after lower extremity vein bypass for CLI. Changes in QoL at 3 and 12 months after lower extremity vein bypass and
multiple predetermined variables potentially influencing QoL after lower extremity vein bypass were analyzed to
determine the effect of lower extremity vein bypass on QoL in CLI patients.
Results: A total of 1404 patients had lower extremity vein bypass for CLI at 83 centers in the United States and Canada
as part of the PREVENT III clinical trial. Surveys were completed in 1296 patients at baseline, 862 patients at 3 months,
and 732 patients at 12 months. The global QoL score (mean  SD) was 2.8  1.1 at baseline and was 4.7  1.4 and 5.1
 1.4 at 3 and 12 months, respectively. Mean changes from baseline at 3 and 12 months were statistically significant (P
< .0001). Improved QoL scores extended across all domains. Diabetes and the development of graft-related events were
associated with decreased improvement in QoL scores, though the mean relative change from baseline remained positive.
Conclusions: Patients with CLI have a low QoL at baseline that is improved at 3 and 12 months after lower extremity vein
bypass. QoL improvements are lower in diabetic patients and those who develop graft-related events. Successful
revascularization can be expected to improve QoL in patients with CLI, with benefits that are sustained to at least 1 year.
(J Vasc Surg 2006;44:977-84.)Limb salvage, graft patency, and operative mortality are
the traditional outcome measures for assessment of infrain-
guinal surgical arterial reconstructions. These variables
have been the focus of much clinical vascular surgical
research for more than 30 years. Anticipated limb salvage
and primary, primary assisted, and secondary patency can
be stratified for proximal and distal anastomotic sites, con-
duit, and indication for surgery (claudication vs limb sal-
vage). More recently, however, the focus has shifted from
lesion- and graft-oriented results to more patient-oriented
results evaluating the effect of arterial reconstructions on
functional outcome and quality of life (QoL). The National
Heart, Lung, and Blood Institute of the National Institutes
of Health states that it “is committed to supporting efforts
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Patients with chronic critical limb ischemia (CLI) are
often elderly with many comorbid conditions that, in addi-
tion to their limb ischemia, may adversely affect their QoL.
Given the advanced age and comorbid conditions of the
CLI patient, the overall effect on QoL of a major surgical
procedure to correct CLI may be questioned. A report
from the Oregon Health & Sciences University indicted
that, despite high patency and limb salvage rates, when
evaluated in terms of variables that would seem tomatter to
patients, only a small minority of patients after an infrain-
guinal arterial vein graft for CLI achieved what was believed
to be an ideal result.2
PREVENT III was a large (1404 patients), multicenter
(83 North American sites), double-blind, randomized clin-
ical trial evaluating the efficacy of intraoperative treatment
of vein grafts with edifoligide to prevent vein graft failure in
patients undergoing infrainguinal arterial reconstruction
with vein grafts for CLI.3 Edifoligide (E2F Decoy, Con-
gentech, Inc, South San Francisco, Calif) is a short piece of
DNA that mimics the binding sequence for E2F.4 The E2F
family of transcription factors is important in the expression
of genes necessary for smooth muscle cell proliferation.5
Theoretically, inhibition of the E2F binding sequence with
edifoligide should decrease smooth muscle cell prolifera-
tion in vein grafts and reduce vein graft failure from intimal
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failure in PREVENT III, and in a companion study of
coronary bypass grafts (PREVENT IV), has been recently
reported.6,7 To date, to our knowledge, it is the largest
randomized clinical trial in patients with CLI.
As part of PREVENT III, the effect of infrainguinal
vein grafting for limb salvage in CLI patients on health-
related QoL was prospectively assessed by using the Vascu-
lar Quality of Life Questionnaire (VascuQol), a validated,
standardized questionnaire. This article details the QoL
data from PREVENT III and suggests an overall favorable
effect of infrainguinal vein grafting on QoL in patients with
CLI. In addition, QoL improvements were positively asso-
ciated with maintained graft patency at 1 year.
METHODS
Trial design. PREVENT III was a multicenter,
double-blinded, randomized, placebo-controlled trial of
edifoligide for the prevention of vein graft failure in patients
undergoing lower extremity bypass for the treatment of
CLI (gangrene, ischemic ulcer, or rest pain). Details of the
trial design have been previously reported.3 The trial was
sponsored by Corgentech Incorporated (South San Fran-
cisco, Calif) and Bristol-Myers Squibb (Princeton, NJ).
Eighty-three sites in the United States and Canada
randomized 1404 patients aged more than 18 years with
CLI to receive either edifoligide or placebo during intraop-
erative preparation of the vein graft. Patients presenting
with only rest pain were required to have vascular labora-
tory evidence of CLI (ankle systolic pressure50 mmHg,
an ankle-brachial index of 0.4, or a toe pressure of 30
mm Hg or a pulse volume recording at the transtarsal level
suggesting severe ischemia).
In addition to grafts arising from a native artery, per-
missible reconstructions also included vein grafts that arose
from a prosthetic patch on the inflow artery and vein grafts
that arose from a prosthetic graft providing inflow to the
groin. Redo vein grafts, spliced vein grafts, and infraingui-
nal bypass in the setting of simultaneous inflow (catheter-
based or surgical) reconstruction were all permitted. Exclu-
sion criteria included claudication alone as an indication for
intervention, a nonautogenous component of the infrain-
guinal graft, and an in situ vein graft (treatment with
edifoligide required ex vivo delivery to the vein graft).
Secondary end points included all-cause failure, primary
graft patency, freedom from clinically significant stenosis,
and assessment of QoL improvement over preoperative
status.
Baseline data. Detailed history and physical examina-
tions were performed at study entry. Comorbid conditions
were characterized from the patient’s interview and prior
medical records, including a history of advanced coronary
artery disease (history of myocardial infarction, coronary
artery bypass grafting, or a percutaneous coronary interven-
tion), symptomatic cerebrovascular disease (prior stroke or
transient ischemic attack), diabetes, hypertension, hyperlip-
idemia, renal failure, prior lower extremity arterial recon-struction (including prior infrainguinal bypass grafts),
chronic obstructive pulmonary disease, and smoking status.
QoL assessment. VascuQolwas used to assess the effect
of CLI and revascularization on health-related QoL. Vascu-
Qol is a disease-specific questionnaire developed to assess the
entire spectrum of chronic limb ischemia, including CLI. It
was developed byMorgan et al in a rigorous two-stage proce-
dure of initial item selection followed by testing for validity,
reliability, and responsiveness to within-patient change. Vas-
cuQol consists of 25 questions in 5 domains: pain (4 ques-
tions), symptoms (4 questions), activities (8 questions), social
(two questions), and emotional (7 questions).8 There is a
seven-point response scale for each question. Responses are
averaged for composite overall and domain-specific scores
from1 to 7. A score of 1 is theworst possibleQoL, and a score
of 7 is the best possible QoL.
Changes in global and domain-specific QoL scores
from baseline were assessed at 3 and 12 months. Patients
with no composite scores were considered nonresponders.
Effect of patient- and procedure-related variables on QoL
were also assessed at 3 and 12 months. The effect of a
graft-related event (GRE; development of a 70% graft
stenosis or having undergone a percutaneous or surgical
revision or amajor amputation) onQoLwas also assessed at
3 and 12 months. Nonresponders and responders at 3 and
12 months were compared at each time interval.
Statistical methods. Changes from baseline of each of
the VascuQol domains and the VascuQol global score were
treated as continuous variables and assessed by using paired
t tests for each time interval. Univariate analysis of the effect
of patient variables (all listed in Table I) and GRE (Table II)
on composite scores was performed with linear regression
for continuous variables (age and weight) and an analysis of
variance via Generalized Linear Models for categorical vari-
ables. Factors that reached a P value of .20 in univariate
analysis (age, baseline weight, indication, prior infraingui-
nal reconstruction, diabetes, dyslipidemia, hypercholester-
olemia, critical stenosis, and loss of patency) were used in a
multivariable mixed effects regression model for repeated
measures as a function of time. Because GREs were covari-
ates, GREs were analyzed individually with patient variables
in the multivariable models. This model also incorporated
survey nonresponders, although a separate and detailed
analysis of survey nonresponders is described below. Other
mixed effects models were created to test time-variable
interactions.
Comparisons between survey responders and nonre-
sponders at 12 months were also performed. Patients who
were deceased at the time of the survey were excluded from
this aspect of the analysis. The Wilcoxon rank-sum test was
used for continuous variables, and the Fisher exact test was
used for categorical variables in univariate analysis. Logistic
regression with backward stepwise elimination was used to
model survey completion in multivariable analysis.
An  value of .05, corresponding to P  .05 and 95%
confidence intervals, was used as a criterion for statistical
significance. Analysis was performed with SAS version 9.1
(SAS Institute, Cary, NC).
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Patient demographics. The details of the demo-
graphics and comorbidities of patients enrolled in the PRE-
VENT III trial have been previously reported.7,8 Pertinent
demographic variables are summarized here. There were
1404 patients who had lower extremity vein bypass as part
Table I. Univariate analysis of patient variables regarding
bypass
Variable
3
Change*
Sex
Race
Weight (per 10-kg increase) 0.01
Age (per 10-yr increase) 0.01
Indication
Rest pain 2.03
Ulceration 1.84
Gangrene 1.90
Prior inflow reconstruction
Prior infrainguinal reconstruction
Yes 1.79
No 1.96
Prior myocardial infarction
Prior coronary bypass procedure
Prior stroke
Diabetes
Yes 1.75
No 2.18
Dialysis
Dyslipidemia
Yes 1.77
No 2.09
Hypertension
*Mean change in global score from baseline.
†P value for intravariable comparison.
Table II. Univariate analysis of graft-related events
regarding change in quality of life at 12 months from
baseline after infrainguinal vein bypass
Graft-related event Change* P value†
Critical stenosis .0001
Yes 1.98
No 2.40
Primary patency .0006
Yes 2.33
No 2.03
Primary assisted patency .0001
Yes 2.34
No 1.70
Secondary patency .0001
Yes 2.31
No 1.70
Freedom from graft-related events .0001
Yes 2.42
No 2.00
*Mean change in global score from baseline.
†P value for intravariable comparison.of the PREVENT III trial (897men and 507women;meanage, 69 12 years). The primary indication for surgery was
ischemic rest pain in 25%, nonhealing ulceration in 39%,
and ischemic gangrene in 36%. The mean preoperative
ankle-brachial index was 0.5  0.4. Sixty-four percent had
diabetes, 73% were smokers, 12% were on dialysis, and 28%
had undergone a previous infrainguinal bypass. Overall,
222 patients (15.8%) died during the study, 18 were lost to
follow-up, and 26 withdrew from the study.
Procedures. The details of the procedures performed
and the results of the PREVENT III trial with respect to
the primary end point of the trial have been previously
reported6,7 and are summarized here. A single segment of
great saphenous vein (reversed or nonreversed) was used in
81% of cases. Fifteen percent of the grafts were composite
vein grafts, and 5% were single-segment non–great saphe-
nous vein grafts. The proximal anastomosis was to the
common femoral, superficial femoral, or profunda femoris
artery in 78%, the popliteal artery (above or below the knee)
in 18%, and other sites in 4%. The distal anastomosis was to
the popliteal artery in 30%, a tibial artery in 55%, and the
dorsal pedal or a plantar artery in 13%.
Surgical outcomes. The details of the postoperative
outcomes of patients enrolled in the PREVENT III trial
have been previously reported6,7 and are summarized here
to provide context for the QoL results. The perioperative
(30-day) death rate was 2.7%. Major morbidity occurred in
17.6%. The 30-day graft occlusion rate was 5.2%, and the
30-day major amputation rate was 1.8%. Major wound
ge in quality of life from baseline after infrainguinal vein
12 mo
P value† Change* P value†
.6258 .6910
.5263 .3081
.1712 0.02 .0185
.040 0.01 .8302
.1677 .1375
2.16
2.13
2.39
.3058 .2985
.0401 .0469
2.10
2.29
.0977 .8043
.2586 .6952
.2477 .8338
.0001 .0968
2.18
2.32
.6219 .1859
.0001 .1181
2.19
2.32
.2898 .7424chan
mocomplications (dehiscence, infection, and necrosis) oc-
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reinterventions were performed on 435 grafts. Assisted
primary patency at 1 year was 77%. Limb salvage at 1 year
was 88%, and survival at 1 year was 84%. There was no
beneficial effect observed in the edifoligide treatment
group for protocol-defined study end points, primary or
primary assisted patency, or limb salvage. Secondary graft
patency was improved at 1 year in the treatment group
(82.6% vs 77.5%; P  .02).7
QoL analysis. QoL evaluations were available from
1296 (92.3%) of patients at baseline, from 862 (61.4%)
patients at 3 months, and from 732 (52.1%) patients at 12
months. There were no differences in changes of QoL
scores from baseline with regard to the global scores or
scores of the individual domains at 3 or 12 months in the
patients whose grafts were treated with edifoligide or pla-
cebo (all P values .221). All comparisons of QoL scores
with baseline values were therefore performed indepen-
dently of the patient’s vein graft treatment group.
Mean global QoL scores increased significantly during
the study period (2.8  1.1 at baseline, 4.7  1.4 at 3
months, and 5.1 1.4 at 12 months), resulting in changes
of1.93 from baseline to 3months,0.34 from 3months
to 12 months, and 2.27 from baseline to 12 months (all
P  .0001). Histograms showing the distribution of the
changes from baseline at 3 and 12 months are shown in Figs
1 and 2. Benefit extended across all domains at 3 and 12
months (all P values .05; Table III).
Results of univariate analysis of the influence of baseline
patient variables on QoL scores are presented in Table I. At
3 months, older age, prior infrainguinal reconstruction,
diabetes, and dyslipidemia were associated with lesser de-
grees of improvement in QoL scores. At 12 months, higher
patient weight and prior infrainguinal reconstruction were
associated with a reduced gain in QoL. Of note, sex, race,
the indication for surgery (rest pain vs tissue loss), coronary
artery disease, stroke, hypertension, and dialysis did not
Fig 1. Quality-of-life changes at 3 months.have a significant effect on QoL changes.The effect of GRE on QoL was significant (Table II).
At 12 months, there was a reduction in the magnitude of
QoL improvements in patients who developed critical graft
stenosis (70% on ultrasonography or angiography;1.98
vs 2.40; P  .0001), loss of primary patency (2.03 vs
2.33; P .0006), loss of primary assisted patency (1.70
vs 2.34; P  .0001), and loss of secondary patency
(1.70 vs 2.31; P  .0001). Overall, patients free from
any GRE had a greater increase in 12-month QoL than
patients with a GRE (2.40 vs2.0; P .0001). Patients
who underwent successful graft revision had lower QoL at
12 months than patients free from any GRE (2.17 vs
2.40; P  .0164). Multivariable analysis showed that
diabetes (P .001 for all models) and GRE (P .0001 for
all models) were related to a reduction in the QoL benefit
experienced at 12 months.
To assess the potential for bias from incomplete sur-
veys, an analysis of survey nonresponders was performed.
Univariate analysis results comparing responders and non-
responders are presented in Table IV. Nonwhite patients
Fig 2. Quality-of-life changes at 12 months.
Table III. VascuQol domain scores
Survey
domain Baseline 3 mo 12 mo
Total, n (%) 1296 (92.3%) 832 (65.7%) 732 (62.5%)
Activity 2.4 (2.1) 4.2 (4.1) 4.5 (4.5)
Emotional 3.0 (2.8) 5.0 (5.3) 5.4 (5.7)
Pain 2.6 (2.3) 4.8 (5.0) 5.3 (5.7)
Social 3.4 (3.0) 5.1 (5.5) 5.5 (6.0)
Symptoms 3.3 (3.3) 5.3 (5.5) 5.5 (5.8)
Overall 2.8 (2.6) 4.7 (4.9) 5.1 (5.3)
Scores are expressed as mean (median) unless otherwise noted. The percent-
age at each time point was calculated as completed surveys/living enrolled
patients. All paired t test comparisons between 3 months and baseline had P
values .0001. All paired t test comparisons between 12 months and
baseline had P values .0001.(P  .0034), diabetics (P  .0338), and patients without
the su
cant P
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nonresponders at 12 months. Patients with GRE were also
more likely to be survey nonresponders: stenosis (P 
.0014), loss of primary assisted patency (P  .0001), and
loss of secondary patency (P .0001) were associated with
survey nonresponse at 12 months. Amputation had the
greatest effect on 12-month survey nonresponse (88% non-
response among eligible amputees vs 31.5% of patients free
of amputations; P .0001), thus effectively precluding any
meaningful measurement of the effect of amputation on
QoL. Multivariable analysis showed that nonwhite race
(P  .01), diabetes (P  .01), loss of primary assisted
patency (P  .0001), loss of secondary patency (P 
.0001), and amputation (P  .0001) were associated with
survey nonresponse, whereas critical stenosis or loss of
primary patency did not have a significant effect.
DISCUSSION
Over the last 40 years, vascular surgeons have fo-
cused on what can be done to salvage ischemic limbs.
The focus of limb salvage surgery is, however, broaden-
Table IV. Univariate analysis of factors associated with su
Variable
Patient-related variables
Sex
Race
White
Nonwhite
Weight
Age
Indication (tissue loss vs rest pain)
Prior inflow reconstruction
Prior infrainguinal reconstruction
Prior myocardial infarction
Prior coronary bypass procedure
Prior stroke
Diabetes
Yes
No
Dialysis
Dyslipidemia
Hypertension
Yes
No
Surgical outcomes
Critical stenosis
Yes
No
Primary patency
Primary assisted patency
Yes
No
Secondary patency
Yes
No
Amputation
Yes
No
*NR indicates nonresponders; total represents patient is alive at the time of
†The factor related to survey nonresponse is given in parentheses for signifiing not only to focus on what can be done, but to alsoconsider what should be done to salvage an ischemic
limb. The effectiveness of limb salvage surgery can be
measured not only in terms of graft patency, survival, and
limb salvage, but also in terms of functional outcome and
overall QoL.9 Prior studies have looked at QoL out-
comes after surgical bypass for lower extremity ischemia.
Studies combining claudication with CLI patients have
shown positive QoL benefits with successful lower ex-
tremity vein bypass.10,11 Early attempts to focus on
expanded parameters of assessing limb salvage surgery
have shown that ideal results, as defined as no further
need for any additional intervention, complete healing of
wounds, and rapid return to independent status, are
seldom achieved long-term in limb-salvage patients.
However, such results do not exclude the fact that
interventions for limb salvage may still improve QoL for
the limb-salvage patient. Indeed, earlier single-center
studies involving only CLI patients showed QoL im-
provements with successful lower extremity vein by-
pass.12 However, to date, to our knowledge, no large,
multicenter, prospective trial has examined QoL out-
response versus nonresponse at 12 months
R/total (%)* P value†
.9497
.0034 (nonwhite)
1/848 (34.3)
8/323 (45.8)
.1933
.8355
.2506
.9999
.6882
.6865
.9438
.9390
.0338 (yes)
3/736 (39.8)
6/435 (33.6)
.3912
.5828
.0264 (no)
0/946 (35.9)
9/225 (44.0)
.0014 (yes)
9/487 (42.9)
0/684 (33.6)
.1741
.0001 (no)
0/883 (29.5)
9/288 (62.15)
.0001 (no)
5/925 (29.7)
4/246 (66.7)
.0001 (yes)
0/125 (88.0)
/1046 (31.5)
rvey.
values.rvey
N
29
14
29
14
34
9
20
23
26
17
27
16
11
329comes after lower extremity vein bypass for CLI.
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efit of edifoligide in preventing vein graft failure,6 it has
provided information regarding outcomes of infrainguinal
limb salvage surgery. It is the first large-scale trial to pro-
spectively assess QoL in patients with CLI. The results
suggest that infrainguinal vein graft surgery substantially
improves QoL in patients with CLI by 3 months after
surgery and that this benefit is maintained at 1 year. Limb-
salvage surgery is therefore appropriate in achieving results
that matter to patients and their families. In addition, these
results can be achieved across a broad spectrum of patients
with CLI and are not limited bymost comorbidities present
in patients with CLI or by the complexity of the required
operation. The study also indicates that GRE adversely
affects QoL, thus suggesting that maintained QoL benefits
are linked to successful surgery and maintenance of graft
patency, at least in the mid-term. However, some improve-
ment from baseline is still seen with most patients who
experience GRE, a finding seen by previous authors.13
Patients free from GRE have more QoL benefits than
patients who undergo graft revision, even when graft revi-
sion is successful. Additional studies to assess the ability of
pharmacologic interventions and other adjuncts to reduce
vein graft stenosis and failure are therefore clearly indicated.
Functional outcome can be measured by using a series
of standardized performance evaluations testing a patient’s
physical abilities.14,15 Changes in QoL after an intervention
are generally measured by using questionnaires adminis-
tered before and after an intervention There are both
overall (eg, Short Form-36, EuroQol, and Nottingham
Health Profile) and disease-specific (eg, VascuQol and
Walking ImpairmentQuestionnaire) instruments.When an
intervention is studied for a specific disease process, disease-
specific questionnaires may have an advantage over more
global assessments of QoL, because disease-specific ques-
tionnaires are designed to assess variables affecting QoL
that are most likely to be influenced by the disease process
being studied.16 The PREVENT III trial was a large,
prospective, multicenter trial that used a disease-specific
questionnaire (VascuQol) designed specifically to assess
both intermittent claudication and CLI.17 PREVENT III
differs significantly in magnitude and design from previous,
much smaller, retrospective or single-institution studies in
this field that also suggested improved QoL after limb-
salvage surgery.8,18 Whereas other questionnaires exist to
assess limb ischemia,19 at the time of the design of PRE-
VENT III, VascuQol was the only disease-specific ques-
tionnaire designed to assess CLI. Other existing validated
questionnaires at the time of PREVENT III design assessed
only intermittent claudication.
There are several potentially important limitations to
this study. First and foremost among these is the potential
bias induced by survey nonresponders. Most survey nonre-
sponse was due to patients not completing the VascuQol
questionnaire at each study visit, although the database
does not provide information on the reasons why. We do
not know whether patients who did not fill out the form
were incapable of filling out the form, were not offered theopportunity to fill out the form, or refused to fill out the
form. An additional cause of survey nonresponse was pa-
tient exit from the trial, because many patients died (16%)
during the study, and a very few (1.3%) were lost to
follow-up or withdrew (1.9%) from participation in the
study. The analysis of the characteristics of the patients who
did and did not fill out QoL forms at months 3 and 12
found that nonwhite patients, diabetics, patients with loss
of patency after revision, and patients with amputations
were more likely to be survey nonresponders. Thus, al-
though conclusions about QoL improvements in patients
with successful limb salvage surgery can be made, conclu-
sions about the magnitude of effect on patients who expe-
rienced a subsequent GRE must be made with great cau-
tion. In particular, amputations were so highly associated
with survey nonresponse (88%) that no meaningful conclu-
sions can be made about the QoL of amputees. Survey
nonresponse is an issue that concerns all survey-based stud-
ies, and our subanalysis of nonresponders identifies poten-
tial omission biases so as to better frame the main study
results.
Although VascuQol was developed by using rigorous
methods common to questionnaires designed to assess
QoL, it is nonetheless a fairly new questionnaire, and
experience with its use is relatively limited. Questionnaires
also do not directly measure functional impairments sec-
ondary to CLI and do not measure the ability of surgery to
improve patient function. Functional outcome (eg, pain-
free walking distance) was not studied in PREVENT III.
We do not knowwhether themagnitude of changes inQoL
measured in this study will correlate with actual patient
functional improvement. In addition, because QoLwas not
a primary end point of the study, the number of survey time
points was limited to three, and no time points beyond the
1-year study follow-up were available. Additional studies to
specifically assess the ability of limb-salvage surgery to
improve patient function are required. Those limitations
notwithstanding, PREVENT III provides the most con-
vincing evidence to date that vein bypass surgery is effective
in salvaging limbs in patients with CLI and can improve
patient QoL, particularly in those patients who experience
maintained patency of their grafts.
CONCLUSIONS
Patients with CLI have a low QoL at baseline that is
improved at 3 and 12 months after lower extremity vein
bypass. QoL improvements are lower in diabetic patients
and those who develop GRE. Successful revascularization
can be expected to improve QoL in patients with CLI, with
benefits that are sustained to at least 1 year.
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The report by Nguyen and colleagues analyzed quality of life
(QOL) data from participants in the PREVENT III trial. Details of
this trial have been previously described.1 Although a negative
trial, PREVENT III is nonetheless significant because it is one of
the largest prospective trials to date related to lower extremity
bypass (LEB) for critical leg ischemia (CLI). QOL issues are
important, and baselines for traditional therapies such as LEB
should be established to allow comparison with alternative, less-
invasive options.
The authors administered validated, disease-specific VascuQol
questionnaires to 1404 patients undergoing LEB for CLI in 83
centers. They concluded that “patients with CLI have a low QOL
at baseline that is improved at 3 and 12 months following LEB.”
QOL improvements were lower in diabetic patients and those
experiencing graft-related events (occlusion or stenosis). They
further concluded that “successful revascularization can be ex-
pected to improve QOL in patients with CLI with benefits sus-
tained to at least one year.”
Although I generally agree with the authors’ conclusions,
there are some problems. The QOL survey response rate was only
61% at 3 months and 52% at 1 year. These relatively low response
rates undoubtedly contribute to a systematic overestimation of the
QOL in CLI patients undergoing LEB. Patients with adverse
outcomes and those who recovered poorly, disappeared into nurs-
ing homes, and were therefore difficult to contact were more likelywhites, diabetics, and patients experiencing graft-related events
were more likely to be survey nonresponders; furthermore, by
multivariable analysis, diabetes and graft-related events were asso-
ciated with decreased QOL at 1 year. Patients who required
amputation were significantly less likely to complete surveys. Thus,
it seems probable that the authors’ analysis paints an overly rosy
picture of LEB QOL outcomes. A more cautious interpretation of
their data is that because of inadequate survey responses at 1 year
and the negative effect of graft failure and amputation that oc-
curred in a significant number of patients, the QOL in the com-
plete cohort of LEB patients is likely to be significantly lower than
that suggested by the data set available for review in this article.
The QOL data reported here are actually more reflective of the
outcome of successful LEB. A similar, parallel conclusion actually
was reported from the BASIL trial, a prospective randomized trial
of open LEB vs percutaneous transluminal angioplasty (PTA) for
CLI. The BASIL trial participants noted that if the patient had a
patent graft at 2 years and was still alive with an intact leg, he or she
subsequently fared better with surgery than with PTA.2 The prob-
lem is that when we initially assess patients for intervention, we do
not know whether they will be alive at 2 years, and we also cannot
accurately predict which patients are likely to have a graft-related
event or amputation.
There are many issues the authors chose not to address in this
article; I hope they will release these issues in larger quanta in
future publications. Particularly, is QOL for patients undergoing
